Adimmune, your trusted partner to global market
We tailor our services to customers’ needs and offer solutions for various scales, phases, and timelines. We are one of the key suppliers of high-quality vaccines and biologics around the world.
View All
Support Resilient
Supply for Vaccines
We engage with the WHO Pandemic Influenza Preparedness Framework to foster the development and access to vaccines. Recognized by US FDA and the EU, we tackle health challenges by leveraging our high standards of quality.
06 Nov. 2026
Protecting Remote Communities and Caring for Vulnerable Groups: Adimmune Donates Influenza Vaccines to the South-Link Region and Nantou County
To protect remote communities, care for vulnerable groups, and eliminate health inequalities, Adimmune donated 500 doses of influenza vaccine to remote areas in the South-Link region this year. Furthermore, to expand assistance to disadvantaged groups, Adimmune, in partnership with Enimmune, donated 400 doses of influenza vaccine for disadvantaged residents aged 19 to 49 in Nantou County. Adimmune emphasized that, guided by its commitment to corporate sustainability, it hopes to support as many people in remote areas and disadvantaged groups as possible and, through influenza vaccine donations, promote a united approach to disease prevention and work together to protect Taiwan.
14 Jul. 2026
Adimmune Showcases New Ready-to-Use Tetanus Vaccine at CPHI Southeast Asia, Expanding Regional Market Opportunities
Adimmune Corporation (TWSE: 4142) showcased its newly launched ready-to-use tetanus vaccine at CPHI (Convention on Pharmaceutical Ingredients) Southeast Asia in Bangkok. The product attracted strong interest from Southeast Asia regional pharmaceutical companies.
09 Jun. 2026
Adimmune Assists Sanofi in Obtaining U.S. FDA Approval for New Manufacturing Line in 20 Months
Adimmune Corporation (TWSE: 4142) today announced another significant milestone in its partnership with global pharmaceutical company Sanofi. To support growing demand in the U.S. market, a second manufacturing line has been added for the partnered product. The project team successfully completed Process Performance Qualification (PPQ) within one year and assisted Sanofi in securing U.S. Food and Drug Administration (FDA) approval for the new line within 20 months, demonstrating Adimmune’s strong capabilities in biologics manufacturing, quality systems, and project execution.
